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a b s t r a c t
Vaccine strain selection for emerging foot-and-mouth disease virus (FMDV) outbreaks in enzootic
countries can be addressed through antigenic and genetic characterisation of recently circulating viruses.
A total of 56 serotype A FMDVs isolated between 1998 and 2012, from Central, East and North African
countrieswere characterised antigenically by virus neutralisation test using antisera to three existing and
four candidate vaccine strains and, genetically by characterising the full capsid sequence data. A Bayesian
analysis of the capsid sequence data revealed the viruses to be of either African or Asian topotypes with
subdivision of the African topotype viruses into four genotypes (Genotypes I, II, IV and VII). The existing




sampled viruses). Three bovine antisera, raised against A-EA-2007, A-EA-1981 and A-EA-1984 viruses,
exhibited broad cross-neutralisation, towards more than 85% of the circulating viruses. Of the three vac-
cines, A-EA-2007 was the best showing more than 90% in-vitro cross-protection, as well as being the
most recent amongst the vaccine strains used in this study. It therefore appears antigenically suitable as
a vaccine strain to be used in the region in FMD control programmes.
ublis© 2014 The Authors. P
. Introduction
Foot-and-mouthdisease (FMD)causes seriousproduction losses
nd has an enormous impact on trade. It is costly and difﬁcult to
ontrol becauseof thediversity of the viruses involved, themultiple
ost species affected (both domestic and over 30 wildlife animal
pecies) and the speed and different routes of transmission. It is
aused by FMD virus (FMDV), a small non-enveloped RNA virus
elonging to the genusAphthovirus in the family Picornaviridae. The
irus exists as seven immunologically distinct serotypes: O, A, C,
sia 1, Southern African Territory (SAT)-1, SAT-2 and SAT-3. Each
erotype has a spectrum of antigenically distinct subtypes due to a
igh mutation rate [1]. The viral genome is about 8.3 kb long and
nclosed in a protein capsid. The capsid comprises 60 copies each
f the four structural proteins (VP1-VP4); the VP1-3 proteins are
ocated on the surface, while VP4 is internal.
∗ Corresponding author. Tel.: +44 1483 232441; fax: +44 1483 232448.
E-mail address: mana.mahapatra@pirbright.ac.uk (M. Mahapatra).
ttp://dx.doi.org/10.1016/j.vaccine.2014.08.033
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article uhed by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
All FMDV serotypes produce a clinically indistinguishable dis-
ease but immunity to one serotype does not confer protection
against another due to the antigenic diversity. The role of humoral
antibodies as the principal component of FMD vaccine-induced
protection is well established [2]. Traditionally, monoclonal anti-
body (mAb) resistant (mar) mutant studies and sequencing of
their capsids have been used to identify critical amino acid (aa)
residues for neutralisation [3–8]. There are four known neutralis-
ing antigenic sites located on the three exposed capsid proteins of
serotype A. Site 1 (G-H loop of VP1) is linear and trypsin-sensitive,
whereas other sites are conformational and trypsin-resistant [5].
Crystallographic studies have identiﬁed thatmost neutralising epi-
topes have been found on surface oriented interconnecting loops
between structural elements [9]. Mutation in an interconnecting
loop may also cause distant effects by perturbation of loop stabil-
ity [10]. The location of antibody binding sites (epitopes) or escape
from binding can also be inferred from correlating the antibody
cross-reactivity of viruses to their capsid sequence similarities [11].
Epitopes can also be predicted, in the absence of antibody recog-
nition data, using different epitope prediction programmes using
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).



























































Homologous neutralisation serum titres of the seven bovine post-vaccinate sera.










and changes in aa was analysed using a general linear modelF.D. Bari et al. / Vacc
iral crystal structure [12]. However, there are no reports for anal-
sis of epitopes or vaccine strain selection studies using serotype A
solates originating from East Africa.
Most FMDoutbreaks in EastAfrica havebeen causedby serotype
, followedbyserotypeAandSAT-2 [13–15]. The serotypeAviruses
re present in all areas of the world where FMD has been reported
nd are diverse both antigenically and genetically. More than 32
ubtypes [16] and 26 genotypes of serotype A FMDV have been
eported [17]. Control of FMD mainly depends on the availability
f matching vaccines that can be selected based on three crite-
ia: epidemiological information, phylogeny of the gene sequence
or evolutionary analysis and serological cross-reactivity of bovine
ost-vaccinal serum (bvs) with circulating viruses [18,19]. Mono-,
i- and quadri-valent vaccines are currently in use in East African
ountries for FMD control [20–22]. These vaccines are mainly pro-
uced in vaccine production plants located in Ethiopia and Kenya
sing relatively historic viruses and regular vaccine matching tests
o select the best vaccine for use in the region are rarely carried out.
ence, the existing vaccines may not provide optimal protection
gainst recently circulating FMD viruses. This studywas, therefore,
esigned to characterise recently circulating FMD viruses in the
egion both antigenically and genetically and recommend match-
ng vaccine strains for use in FMD control program in East African
ountries.
. Materials and methods
.1. Cells and viruses
Fifty-six serotype A viruses from Africa submitted to the World
eference Laboratory for FMD (WRLFMD) at Pirbright were used
n this study. These viruses were from ﬁve East African countries,
thiopia (n=8), Eritrea (n=9), Sudan (n=6), Kenya (n=6), Tanzania
n=7) and fromthreeneighbouringcountries:DemocraticRepublic
f Congo (COD, n=5), Egypt (n=10) and Libya (n=5). These samples
reknowntohavebeenderived fromcattle epithelial tissuesexcept
ight viruses from Egypt and one virus from Kenya where the host
pecies is not known (Supplementary Table 1). All the sampleswere
nitially grown in primary bovine thyroid cells (BTY) with subse-
uent passage in either BHK-21 or IB-RS2 cells. The virus stocks
ere prepared by infecting cell monolayers and stored at −70 ◦C
ntil use. Viruses are named according to a three letter code for the
ountry of origin followed by the isolate number and the year of
solation, e.g. A-COD-02-2011. Candidate vaccine strains are desig-
ated by a two letter code for East Africa followed by the year of
solation, e.g. A-EA-2005.
.2. Polyclonal sera
Seven anti-FMDV bovine post-vaccinal sera were used in the
tudy. Two were against the two existing vaccine strains, A-KEN-
5-1980 and A-ETH-06-2000 raised in Kenya and Ethiopia [21],
espectively, by administering the commercially prepared vaccine.
he animals vaccinated with A-KEN-05-1980 were bled on 21
ay following vaccination. The animals vaccinated with A-ETH-06-
000 received a boost on 21-day post-vaccination and bled one
eek later. The rest ﬁve bvs were raised in cattle against one exist-
ng vaccine strain (A-ERI-1998) and four candidate vaccine strains
A-EA-1981, A-EA-1984, A-EA-2005 and A-EA-2007) following the
ethod previously described [23]. The candidate vaccine strains
ere selected taking into account the genotypes currently circu-
ating in the region. For each antigen, sera from four or ﬁve animals
ere pooled for use in the neutralisation test. The homologous
eutralising antibody titres of each pooled serum are presented
n Table 1a.A-ETH-06-2000 5 1.99
The vaccines are arranged in decreasing order of serum titre.
2.3. Two-dimensional micro-neutralisation test (2D-VNT)
The 2D-VNT test was carried out using the pooled post-
vaccination bovine sera according to Rweyemamu and colleagues.
[24]. Antibody titres were calculated from regression data as the
log10 reciprocal antibody dilution required for 50% neutralisa-
tion of 100 tissue culture infective units of virus (log10SN50/100
TCID50). The antigenic relationship of viruses is given by the
ratio: ‘r1’ = neutralising antibody titre against the heterologous
virus/neutralising antibody titre against the homologous virus. The
signiﬁcance of differences between ‘r1-values’ obtained by the
polyclonal antiserum was evaluated according to standard criteria
[25].
2.4. Nucleotide sequencing and analysis of the sequence data
The sequences of the entire capsid coding region (P1) of the
viruseswere generated. RNAextraction from the cell culture grown
viruses, reverse transcription (RT), polymerase chain reaction (PCR)
to amplify the P1 region, sequencing, sequence analysis and assem-
bling, and alignment were performed as described previously [26].
MEGA 5 [27] was used to determine nucleotide and aa variations.
The aa variability of the capsid coding region of the type A viruses
were determined as described by Valdar [28].
2.5. Genetic characterisation
The aligned, complete P1 nucleotide sequences were used to
determine the most suitable nucleotide substitution model using
jModelTest [29] and MEGA [27] resulting in the selection of a
General time reversal (GTR) model with a combination of gamma
distribution and proportion of invariant sites (GTR+G+ I). Then,
Bayesiananalysiswasperformedusing theBEASTsoftwarepackage
v1.5.4 [30]. In BEAUti v1.5.4, the ages of the viruseswere deﬁned by
thedateof sample collectionand theanalysisusedGTR+G+ Imodel
to describe rate heterogeneity among sites. Variations in substi-
tution rate among branches were evaluated by comparing four
different clocks in BEAST. The maximum clade credibility (MCC)
phylogenetic tree was inferred using the Bayesian Markov Chain
Monte Carlo (MCMC) method. Then, a Bayes factor analysis in
TRACER version 1.5 [31] was used to determine the best-ﬁt model
that resulted in the selectionof anuncorrelatedexponential relaxed
molecular clock. The tree was obtained using the Tree Annota-
tor program in BEAST and the evolutionary trees were viewed in
FigTree program 1.3.1.
2.6. Statistical analysis
The relationship between predicted protection (r1-value ≥0.3)(GLM)withbinomial error distribution. For this, a binomial variable
‘protected/not protected’ was created based on the estimated r1-
values ≥0.3 (protected), which was used as the response variable.
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Table 1b
Predicted in vitro protection provided by individual vaccine strains against ﬁeld viruses per country.




A-ETH-06-2000*, $ A-EA-1981 A-EA-2007$ A-ERI-1998*,# A-KEN-05-1980*,£ A-EA-2005£ A-EA-1984#
Ethiopia$ 8 7/8 8/8 8/8 3/8 0/8 6/8 8/8
COD£ 5 1/5 4/5 5/5 3/5 0/5 5/5 5/5
Kenya£ 6 2/6 6/6 6/6 3/6 3/6 3/6 5/6
Tanzania£ 7 2/7 6/7 7/7 1/7 0/7 7/7 7/7
Eritrea# 9 3/9 9/9 9/9 9/9 0/9 7/9 9/9
Sudan# 6 3/6 4/6 6/6 5/6 0/6 6/6 6/6
Egypt$,# 10 2/10 8/10 7/10 2/10 0/10 7/10 9/10
Libya 5 0/5 5/5 3/5 0/5 0/5 1/5 0/5

























dCommercial vaccine in use. Countries and vaccine viruses having the same supers
oxes indicate best vaccines for each country. Where multiple vaccine strains pro
losest genetic relationship to the viruses circulating within the country.
ummaries of the aa count differences between the query sequence
f thevaccine strain and thoseof theﬁeldviruseswereusedas inde-
endent variables using either entire P1 aa sequence and each of
he different viral proteins (VP1-4), alone or in combination. Both
ariables were analysed independently in a univariate analysis and
ogether in amultivariate analysis. TheGLMmodelling and analysis
f the data was carried out using R [32].
. Results and discussion
In FMD endemic settings, implementation of the progressive
isease control pathway [13] requires vaccines that can protect
gainst both circulating and emerging variants, regular vaccina-
ion campaigns, post-vaccination sero-monitoring and biosecurity
easures in the form of livestock movement control. Therefore,
election of appropriate vaccine strains is an important element
n implementing vaccination policies for the control of FMD.
MD is enzootic in East Africa, with outbreaks reported regularly
15,33–35]. Although the region has two vaccine producing plants,
here is little information available on the protective value of the
upplied vaccines. The only report on vaccine strain selection in
ast Africa [21] was limited to a small selection of Ethiopian vac-















ig. 1. Antigenic relationship (r1) values of 56 East Africa type A isolates. The serological m
otted line indicates the cut-off value of 0.3, above which the vaccine is considered to be£-genotype I, #-genotype IV, $-genotype VII) belong to the same genotype. Shaded
quivalent expected protection, the best recommendation is for the one with the
viruses such as A-KEN-05-1980 (A/K/5/80) and A-KEN-35-1980
(A/K/35/80) for vaccine production [22] and the vaccine matching
tests are seldom carried out [15]. In these settings, where emer-
gence of new variants is unpredictable, especially for serotype A
FMDV, continuous serological and genetic characterisations of ﬁeld
viruses is needed to understand the cross-reactivity of existing vac-
cines and to trace patterns of viral spread.
3.1. Serological characterisation of serotype A FMD viruses
In this study, the ability of the three existing vaccine strains (A-
ERI-1998, A-ETH-06-2000 and A-KEN-05-1980) and four putative
candidate vaccine strains (A-EA-2007, A-EA-1984, A-EA-2005 and
A-EA-1981) of serotype A FMDV to cross-protect (in-vitro) against
the circulating viruses was measured by 2D VNT. The three exist-
ing vaccine strains were found to be least cross-reactive (r1-values
≥0.3 observed for only 5.4–46.4% of the sampled viruses) suggest-
ing a poor suitability in the ﬁeld, unless the low antigenic match
can be compensated for by highly potent vaccine formulations
[36]. However A-ETH-06-2000 and A-ERI-1998 exhibited good
cross-reactivity against viruses within their respective genotypes
and also the viruses from their respective countries (Table 1b).
The viruses not neutralised by the seven bvs were the Asian
topotype (A-Iran-2005 strain) viruses. The most broadly reactive
A-EA-1984A-ERI-1998A-EA-2005N-05-1980
es
atch (r1-values) of the seven vaccine strains is shown as black dots. The horizontal
a good match.
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Table 2a
Percentage (%) nucleotide and amino acid variability in the capsid sequences of the serotype A FMD viruses.
Capsid region Total no. of nt positions aligned No. of variable nt % nt variability Total no. of aa positions aligned No. of variable aa % aa variability
VP1 633 295 46.6 211 71 33.65
VP2 654 251 38.38 218 38 17.43
VP3 663 250 37.71 221 41 18.55











































CP1 2205 882 40
t: nucleotide, aa: amino acid, %: percent.
ntisera were A-EA-2007, A-EA-1981 and A-EA-1984 exhibiting
1.1%, 89.3% and 87.5% in-vitro protection, respectively, (Fig. 1 and
able 1b) and could be strong candidates to be developed as vac-
ine strains. However A-EA-1984may not be suitable for the region
s the A-Iran-05 like viruses circulating in Libya were not covered
y this vaccine at all (Table 1b). There is evidence of incursion of
he viruses circulating in theMiddle East into African countries like
gypt and Libya because of animal trade between these countries
37]. Therefore these virusesmay also be subjected for an antigenic
atch along with East African outbreak viruses, as these viruses
ay spread into East African countries because of unrestricted
nimal movement between African nations. Since developing and
aintaining two vaccine strains for use along with the associated
uality control and vaccine potency tests is not very attractive to
accine manufacturers, it would be better to select a single strain,
uch as A-EA-2007 that showed broad cross-reactivity to the circu-
ating strains of different genotypes and topotypes. A ﬁnal decision
ould need to take account of other criteria, such as the virus yield
n cell culture and the stability of the antigen produced.
.2. Genetic characterisation of the serotype A viruses
The full capsid sequences of the 56 serotype A viruses gener-
ted in this study were 2205 nucleotides (nt) long. The viruses
howed a total of 882 (40%) nt and 158 aa (21.5%) aa substitutions
cross P1 (Table 2a). Compared to the oldest virus A-KEN-05-
980 there was 0.2% (A-KEN-01-2003) to 23.7% (A-EGY-08-2011)
ucleotide variation between these viruses. Analysis of the capsid
mino acid sequences revealed 0.3% (A-KEN-01-2003) to 9.5% (A-
GY-08-2011) aa variation. Similarly, compared to the best vaccine
irus, A-EA-2007, there were 3.3% (A-ETH-13-2009) to 25.2% (A-
GY-05-2011) nucleotide variation and the amino acid variation
as found to be 0.1% (A-ETH-07-2008) to 8.6% (A-EGY-05-2011,
-EGY-01-2010, A-LIB-21-2009).
The analysis of the capsid aa residues of the type A viruses
evealed a large number of sites across the capsid having 4–8 alter-
ative aa (Table 2b). Notably, sequences for VP2-191 encoded eight
ifferent amino acids (A/N/D/Q/G/H/S/T) and exhibited nt changes
t all the three positionswithin the codon (Table 2b) as didVP2-134
A/N/E/Q/P/T/V) and VP1-197 (A/G/L/P/S/T/V) giving rise to seven
lternative amino acids. Recently, residues VP1-197 and VP2-191
ere predicted as epitopes for serotype A FMD viruses using vari-
us epitope prediction software [12]. VP2-191 has also been shown
o be of antigenic signiﬁcance in case of serotype O viruses [38].
able 2b
apsid positions where multiple amino acid substitutions were observed. Numbers in pa
Viral protein Number of alternative aa residues
4 5
VP2 71 (27),74 (27), 78 (27), 86 (32), 131
(6), 173 (31)
64 (12)
VP3 70 (29),139 (12) 220 (30)
VP1 24 (17), 96 (21), 101 (24), 110 (29), 139
(32), 140 (28), 142 (29), 148 (16), 149
(30), 194 (9)
44 (33), 141(29), 196735 158 21.5
VP2-134 is located adjacent to VP2-132, a known neutralising epi-
tope in serotype A10 [6]. In addition, this residue has been reported
to strongly inﬂuence the binding of neutralising antigenic site 2
mAbs in serotype O FMDV [39]. Therefore, these residues could
be of antigenic signiﬁcance in serotype A viruses which requires
further investigation.
3.2.1. Bayesian phylogenetic analysis
Phylogenetically, the viruses were grouped into two topotypes
(AfricanandAsian)within serotypeAFMDV. InEastAfrica, only four
genotypes (I, II, IV, and VII; Fig. 2) of African topotype viruses were
found to be circulating, along with four viruses from Egypt and ﬁve
viruses from COD. Interestingly, all the viruses isolated from COD
belong to genotype I (Fig. 2), similar to isolates from neighbouring
countries suchasTanzaniaandKenya, suggestingcross-border live-
stockmovement and/or trade between these countries as observed
in Uganda [40], Libya and Egypt [37].
A-EA-1981 virus was assigned to genotype II, however no fur-
ther viruses of this genotype have been detected in the region
since. The Asian topotype viruses (A-IRAN-2005 like viruses) were
detected only in Egypt and Libya. These viruses were also detected
in 2013 in Egypt and may still be circulating in the region. The sce-
nario in Egypt is further complicated by circulation of two African
genotypes (G IV and VII; Fig. 2) thereby making FMD control very
difﬁcult. The introduction of A-IRAN-2005 like viruses to Africa
could be the result of trade between the Middle East and African
countries [37].
3.2.2. Rate of nucleotide substitution
BEAST analysis using selected models revealed that the mean
rate of nucleotide substitution in the capsid coding region of
the viruses (year of isolation 1964 to 2012) was estimated to
be 3.09×10−3 substitution/site/year (95% HPD 2.02×10−3 to
4.16×10−3). This is lower than the rate reported for VP1 sequences
of serotype A viruses [41] and that for P1 sequences of A-Iran-05
like viruses from the middle-East [26].
Themean estimate of the time of emergence for themost recent
common ancestor was found to be about 128 years before the
present (ybp) [95% highest posterior density (HPD): 69 to 212]. This
compares to a previous estimate of about 178 ybp (in 1823) for
the emergence of serotype A viruses [41]. According to our estima-
tion, the common ancestor of East Africa serotype A viruses existed
around 1926 (Fig. 2).
renthesis indicates number of isolates in which these changes were observed.
6 7 8
133 (26) 134 (38) 191 (41)
71 (30) – –
(21), 198 (31) 43 (24), 45 (33), 99 (40) 197 (32) –

























Cig. 2. Bayesian phylogenetic tree of the FMDV serotype A isolates from East Africa
enbank are indicated by their respective accession numbers. The stars indicate th
.3. Amino acid variability of the capsid of the type A viruses from
ast Africa
Analysis of the variability of the capsid amino acids of the type
viruses from East-Africa revealed VP4 to be highly conserved and
P1 to be highly variable (Table 2a and Fig. 3a); similar to earlier
eports on type A viruses from the Middle East [26]. The residues
ith a score greater than 1.0 (16 in VP1, 10 in VP2 and 3 in VP3)
re shown in Fig. 3a indicating that more than 50% of the residues
ith a high variability score are present in VP1. All but two (VP1-33
nd VP2-207) of these residues were found to be surface exposed
Fig. 3b–d).
.4. Correlating cross-reactivity with capsid amino acid changes
The association between the numbers of aa changes and the
erological reactivity (expressed as probability of protection; r1-
alue ≥0.3) between vaccine and virus strain pairs was assessed
sing a GLMmodel. This analysis was done for the whole P1 region
nd for the four individual structural proteins (VP1-4) either alone
r in combinations. First, a univariate analysis was carried out,
hich showed that the number of changes in the P1 and VP4 pro-
eins did not correlate to in-vitro cross-protection, whereas a link
as evident for the three surface-exposed proteins (VP1-3), with
P3 showing the strongest association (P<0.001). A subsequent
ultivariate analysis to evaluate the three different VP regions
nd their interactions did not identify any signiﬁcant interactions.
hanges in VP3 and VP2 showed a signiﬁcant (negative) effect onree neighbouring countries. The reference capsid sequences (n=10) retrieved from
ine viruses.
the probability of protection; the higher the number of changes the
lower the probability of protection (Supplementary Table 2). The
absence of a relationship between predicted protection of vaccines
and changes in capsid aa of ﬁeld viruses observed in our analysis is
in keeping with other evidence that neutralisation is governed by
key (mutant-) capsid aa residues, and probably by residue inter-
actions, rather than overall residue changes [10]. However, the
observation of a relationship between predicted protection and the
substitutionof aa inVP3 is interesting. Assessing the contributionof
speciﬁc substitutions to predicted cross-protection requires more
advanced analytical approaches and manipulation of selected aa
residues using reverse genetics approaches.
The multivariate analysis also allowed a comparison of the
predicted level of cross-protection provided by each of the
commercial and candidate vaccine strains used in this study. A-
EA-2007, A-EA-1984 and A-EA-1981 exhibited signiﬁcantly higher
expected protection with A-EA-2007 exhibiting the highest odds
value (Table 3). A-ETH-06-2000 was not signiﬁcantly different
from A-ERI-1998, while A-KEN-05-1980 was signiﬁcantly less
protective than A-ERI-1998. The vaccines (A-ETH-06-2000 and
A-KEN-05-1980) showing the lowest in-vitro cross-protection
based on r1-values (Fig. 1) also showed the lowest odd values
(Table 3).
In conclusion, two topotypes (African and Asian) of the type A
viruses were detected in East Africa; of the native African topo-
type three genotypes are currently circulating in the region. We
have recommended different vaccines for the different genotypes
based on their serological cross-reactivity and genetic relationship.
F.D. Bari et al. / Vaccine 32 (2014) 5794–5800 5799










































































Fig. 3. (a) Capsid amino acid variability of the type A viruses from East-Africa. The vertical black dotted line indicates gene junction. ((b)–(d)) 3D structure of Type A protomer
of A1061 (1ZBE) showing highly variable capsid amino acid residue (with a score ≥1) h
cartoon; (c) external surface (d) internal surface. (For interpretation of the references to c
Table 3
Odds of protection of all vaccines with reference to vaccine strain A-ERI-1998 was
used as reference vaccine for model selection as it is the best amongst the commer-
cially available vaccines.
Vaccine Odds value 95% conﬁdence interval P-value
A-ERI-1998 1 – –
A-EA-2007 36.17 11.57–135.02 P<0.001
A-EA-1984 29.85 9.54–109.92 P<0.001
A-EA-1981 16.25 5.56–54.90 P<0.001













GA-ETH-06-2000 0.73 0.31–1.70 P>0.5
A-KEN-05-1980 0.06 0.01–0.21 P<0.001
-EA-2007 has broader cross-reactivity and is also a recent isolate;
herefore, is recommended as a potential vaccine strain candidate
o be used in FMD control programs in East Africa, subject to good
rowth and stability characteristics and in vivo evaluation in the
arget host.
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